DRUG vs RIGL
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 01, 2026
DRUG
RIGL
Investment Advisor Scores
RIGL
AI Analyst Insights
Detailed Metrics Comparison
| Metric | DRUG | RIGL | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 9.2851 | Tie |
| PEG Ratio | 0 | -0.1 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 0.0% | -22.6% | DRUG |
| Earnings Growth | 0.0% | -73.2% | DRUG |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 49.0/100 | 45.8/100 | DRUG |
| Profit Margin | 0.0% | 116.3% | RIGL |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
DRUG
MarkdownPrice below a falling SMA50 (slope -6.7%), weak momentum, RSI 22
RIGL
MarkupPrice above SMA50, rising 50-day trend (7.0% over 20 days), RSI 52
Fundamentals Snapshot
| Metric | DRUG | RIGL |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -6.0 | 9.5 |
| Trailing P/E | — | 2.9 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | -0.2% |
| Gross Margin | — | 0.8% |
| Operating Margin | 0.0% | 0.3% |
| EPS | -2.00 | 16.64 |
| Dividend Yield | — | — |